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On examination, the patient 
was cold and clammy, with 
an unrecordable blood 
pressure. The ECG showed 
monomorphic ventricular 
tachycardia, at a rate of 180/minute (Fig. 1). 
Direct current cardioversion was performed 
and a repeat ECG (Fig. 2) revealed sinus 
arrest with partial right bundle branch block. 
She underwent temporary transvenous pacing 
and was admitted to the cardiac intensive 
care unit. Admission blood tests confirmed 
digoxin toxicity: serum digoxin concentration 
3.2 ng/mL (normal range: 0 - 2). Administration 
of the digoxin, atenolol and amiodarone was 
immediately discontinued; the arrhythmia 
gradually improved over the next day (Fig. 3). A 
final diagnosis of digoxin toxicity complicated 
by ventricular tachycardia, sinus arrest and 
1st-degree atrioventricular (AV) block was 
made. The patient was discharged from hospital 
feeling much better, and digoxin therapy was 
discontinued.
Discussion
First described in 1785 by William 
Withering, cardiac glycosides have been 
used in the treatment of heart failure 
for >200 years,[1] and digoxin had been 
the most commonly used of these 
compounds. Owing to adverse effects 
and the availability of improved drugs 
for heart failure, its popularity as the 
drug of choice has declined. Digoxin 
has a positive inotropic effect, shifts 
the Frank-Starling curve upward and 
leftward, and results in greater stroke 
volume generation for a given myocardial 
contraction,[2] achieved through altered 
balance in the handling of intracellular 
Na+ and Ca2+ from its potent inhibition 
of the Na+/K+ ATPase. Increased 
intracellular Ca2+ potentiates the action 
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A 67-year-old woman presented to the Emergency Unit, Groote Schuur Hospital, Cape Town, South Africa, with a 1-week history of 
poor appetite, vomiting and fatigue. Her background history was notable for infundibular pulmonary stenosis resection, pulmonary 
embolism and atrial flutter. Two days before, she complained to her general practitioner of recent-onset, recurrent syncope and worsening 
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atenolol 50 mg twice daily, amiodarone 200 mg daily and digoxin 0.125 mg daily. The digoxin was added to her therapy 8 months earlier to 
optimise rate control. 
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Fig. 1. ECG on admission: regular broad complex tachycardia (QRS 320 ms), ventricular rate 180/minute, 
QRS axis −70°. No clear p waves on the strip. Features consistent with ventricular tachycardia. 
Fig. 2. Post-cardioversion ECG: irregular broad complex rhythm, QRS duration 160 ms, ventricular rate 
18/minute, atrial rate 18/minute, right bundle branch configuration. Diagnosis: sinus arrest. 
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of myocardial contractile proteins.[2] At 
physiological levels, digoxin slows the sinus 
rate, prolongs the AV node refractory period 
and has parasympathomimetic effects.[3] 
At toxic concentrations, digoxin leads 
to arrhythmias secondary to increased 
cell excitability from decreased resting 
cellular membrane potentials and after 
depolarisations.
Up to 80% of ingested digoxin is absorbed, 
with a half-life of 36 - 48 hours (which 
is significantly increased in patients with 
renal disease).[4] Owing to extensive fat 
distribution, dialysis is ineffective in 
removing digoxin.[1] Furthermore, digoxin 
has multiple metabolic effects (including 
hypokalaemia, hypomagnesaemia and hypo-
calcaemia) and drug interactions, which 
accentuate its toxicity. Concomitant use of 
diuretics increases the incidence of digoxin 
toxicity by decreasing the glomerular 
filtration rate and inducing electrolyte 
imbalances. Administration with other 
anti-arrhythmic agents may provoke pro-
arrhythmic events.[3]
Clinical manifestations of digoxin toxicity 
are cardiac and extracardiac. Cardiac 
manifestations can be classified as follows:
• Ectopic rhythms due to re-entry or 
enhanced automaticity: atrial tachycardia 
with a block, junctional tachycardia, 
ventricular premature complexes, 
ventricular tachycardia.
• Depression of pacemakers: manifested as 
sinus arrest.
• Depression of conduction: manifested 
as AV block or sinoatrial node exit 
block. First-degree AV block and Mobitz 
type Ι 2nd-degree AV block are common 
manifestations. Mobitz type ΙΙ 2nd-degree 
AV block and complete AV block are rare 
presentations of digoxin toxicity.
• Limited effect on the bundle branches: 
bundle branch block or intraventricular 
conduction delay are rare features of 
toxicity.[5]
Extracardiac features of digoxin toxicity 
include anorexia, nausea and vomiting (in up 
to 70% of patients), visual disturbances and 
hyperkalaemia. 
Evidence from historical studies, 
conducted before the introduction of 
β-blockers for the treatment of heart failure, 
supports the use of digoxin in patients with 
left ventricular systolic dysfunction, particularly 
in those with advanced symptoms.[6] There is, 
however, no evidence that digoxin improves 
survival – it may even worsen outcomes. 
The Digitalis Investigation Group (DIG) 
Trial, a study of almost 6 800 patients with 
symptomatic heart failure, left ventricular 
ejection fraction <45%, and in sinus 
rhythm, assigned randomly to receive either 
digoxin or placebo, showed the following 
results after 3 years of follow-up: (i) there 
was no difference in survival between 
the digoxin and placebo groups; (ii) the 
patients on digoxin had fewer symptoms 
and were hospitalised less often for heart 
failure; (iii) patients on digoxin showed a 
significant increase in non-heart failure 
deaths, including deaths from arrhythmia, 
particularly in women; and (iv) lower serum 
digoxin levels correlated with survival.[7] 
It is imperative to identify patients 
at risk of toxicity and deter mine their 
haemodynamic status. In stable patients, 
withdrawal of digoxin and close moni-
toring may be sufficient.[2] In unstable 
patients, identification and treatment of 
the associated arrhythmia and correction 
of electrolyte imbalances that may 
accompany and exacerbate digoxin toxicity 
are advised.[2] Digoxin-specific human 
immunoglobulin fragments are indicated 
in the setting of intractable arrhythmias 
and haemodynamic compromise.[1,2]
In summary, this case serves as a timely 
reminder that careful consideration and 
thought should be given prior to the use 
of cardiac glycosides. Although frequently 
used in the treatment of heart failure with 
low ejection fraction and atrial fibrillation/
flutter, for symptomatic benefit and decreased 
hospitalisation rates these drugs offer no 
survival benefit and may be associated with 
worse outcomes.[6] Close monitoring and dose 
adjustment are required in elderly patients 
and those with renal impairment, and when 
used with other anti-arrhythmic drugs. 
Indeed, in an article in the Forum section 
in this edition of SAMJ, Opie[8] states that 
there are few arguments in favour of the use 
of digoxin to control rate in atrial fibrillation.
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Fig. 3. Day 1 after withdrawal of anti-arrhythmic drugs: sinus rhythm, rate 48/minute, axis −15°, 
PR interval 240 ms, broad QRS (160 ms), right bundle branch block configuration. Assessment: sinus 
rhythm and right bundle branch block and 1st-degree AV block.
